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Low- and middle-income countries (LMICs) shoulder the bulk of the global burden of infectious diseases and
drug resistance. We searched for supranational networks performing antimicrobial resistance (AMR) surveillance
in LMICs and assessed their organization, methodology, impacts and challenges. Since 2000, 72 supranational
networks for AMR surveillance in bacteria, fungi, HIV, TB and malaria have been created that have involved
LMICs, of which 34 are ongoing. The median (range) duration of the networks was 6 years (1–70) and the num-
ber of LMICs included was 8 (1–67). Networks were categorized as WHO/governmental (n"26), academic
(n"24) or pharma initiated (n"22). Funding sources varied, with 30 networks receiving public or WHO funding,
25 corporate, 13 trust or foundation, and 4 funded from more than one source. The leading global programmes
for drug resistance surveillance in TB, malaria and HIV gather data in LMICs through periodic active surveillance
efforts or combined active and passive approaches. The biggest challenges faced by these networks has been
achieving high coverage across LMICs and complying with the recommended frequency of reporting. Obtaining
high quality, representative surveillance data in LMICs is challenging. Antibiotic resistance surveillance requires a
level of laboratory infrastructure and training that is not widely available in LMICs. The nascent Global
Antimicrobial Resistance Surveillance System (GLASS) aims to build up passive surveillance in all member states.
Past experience suggests complementary active approaches may be needed in many LMICs if representative,
clinically relevant, meaningful data are to be obtained. Maintaining an up-to-date registry of networks would
promote a more coordinated approach to surveillance.
Introduction
The burden of drug-resistant infections is increasing year on year.
It has been predicted that the largest numbers of lives that will be
lost as a result of these infections will be in low- and middle-
income countries (LMICs).1 A global action plan on antimicrobial
resistance (AMR) was endorsed in May 2015 by the World Health
Assembly and calls upon countries to strengthen AMR surveillance.
It is generally accepted that we need good AMR surveillance data
to be able to assess the scale of the problem accurately and to
guide interventions. Many LMICs are already participating in sur-
veillance initiatives for AMR in malaria, TB, HIV and influenza.
Attempts to kick-start global surveillance for resistance to com-
monly used antibacterial drugs have been made in the past but
generally without success. The Global Antimicrobial Resistance
Surveillance System (GLASS) was launched in 2015 with the goal
of collecting comparable AMR data at country level for key bacte-
rial pathogens.2 At the same time, the recent catastrophic Ebola
epidemic in West Africa has brought the need for surveillance for
emerging or epidemic-prone diseases into sharp focus, as experi-
ence has shown the majority of these have their origins in LMICs.
The interaction between different drivers in humans, animals and
the environment argues for adopting a ‘One Health’ approach to
surveillance for both AMR and emerging diseases.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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Here, we summarize the supranational surveillance networks
for drug-resistant infections operating in LMICs since 2000 and dis-
cuss their impacts and challenges, and any implications for the
implementation of GLASS.
Methods
For the purposes of this analysis, AMR was defined as resistance to antimi-
crobial agents in bacteria, protozoa, fungi and viruses. Countries were cate-
gorized into income groups using the World Bank 2015 classification.3
Search strategy
We searched for supranational networks performing AMR surveillance in
LMICs from January 2000 to August 2017 in Embase, PubMed and Global
Health databases. The search was performed first in May 2016 and
updated in August 2017. Search terms were broad and included multiple
alternative terms for AMR (e.g. drug resistance, antibiotic resistance, anti-
fungal resistance, antimalarial drug resistance, antiviral resistance, cross
resistance, multidrug resistance), as well as alternative terms for surveil-
lance and for LMICs, which were also searched for individually by name
(the complete list of search terms is available as Supplementary data at
JAC Online). The titles and abstracts or full text of 20 558 (16 629 in 2016
plus 3929 in 2017) articles were screened to identify networks.
Networks did not have to collect primary samples to be included, i.e.
they could collate resistance data collected by other groups. We excluded
networks that occasionally reported drug resistance but did not have AMR
surveillance as the major focus of their activity, e.g. a global travel-
associated infection surveillance network, several One-Health networks
and the Digital Disease Detection networks (e.g. ProMed). Networks were
categorized by type (WHO/governmental, academic, pharmaceutical com-
pany/contract research organization-led or other), target pathogen group-
ing (bacteria, TB, malaria, HIV, other) and funding source. Networks
performing AMR surveillance in bacteria were further characterized by
pathogen sub-group (e.g. respiratory, enteric) and population under surveil-
lance (e.g. community versus hospital-acquired infection, children). We
noted the approaches to quality management taken and impacts or chal-
lenges of the networks when recorded.
Results
We identified 72 supranational networks concerned with AMR sur-
veillance since 2000, of which 26 were WHO/governmental (global
or regional), 24 academic and 22 pharma initiated (Figure 1).
Funding sources varied, with 30 networks receiving public or WHO
funding, 25 corporate, 13 trust or foundation, and 4 funded from
more than one type of source. The data-sharing models of the net-
works were open access (n"3), closed (n"38) and shared or
unclear (n"31).
In terms of the pathogens under surveillance, 45 networks
were for AMR in bacteria or fungi (Table 1), 18 in malaria, 2 in TB,
6 in HIV and 1 for influenza (Table 2). The median (range) duration
of the networks was 6 years (1–70). In the case of the discontinued
malaria networks, inability to secure sustainable funding was an
important reason for their collapse.4 Coverage of LMICs by the net-
works varied greatly. The median (range) number of LMICs
included in the AMR surveillance networks for which the informa-
tion was available was 8 (1–67). The WHO Global Influenza
Surveillance and Response System (WHO GISRS) was the longest
running network, established in 1947, and included the greatest
number of LMICs (67), although antiviral resistance was not under
surveillance at the outset.
Networks for AMR surveillance in bacterial pathogens
Of the 44 networks focused on AMR in bacteria, 6 reported data on
the GLASS priority pathogens (with the exception of Salmonella
spp. in 4), 2 networks were for Staphylococcus aureus, 10 were for
respiratory pathogens (2 of these included Neisseria meningitidis
and 1 enteric pathogens), 4 were for enteric pathogens only, 1 was
for Neisseria gonorrhoeae and the remainder included a range of
Gram-negative (5) or Gram-positive (2) bacteria or a mixture of the
two. Seven networks collected or reported data on invasive isolates
only, five non-invasive only and the remainder both. For those net-
works that specified the patient populations isolates came from,
seven were community-acquired, five hospital-acquired, one was
in women and four in children.
Differences between network categories
The networks were a heterogeneous group with different approaches
to surveillance reflecting different objectives. The greatest diversity
was found in the antibacterial surveillance group. Most global net-
works initiated and sponsored by pharmaceutical companies had the
objective of evaluating susceptibility to specific drugs (registered
drugs or new compounds). A variety of bacterial or fungal pathogens
were collected by the pharma networks including community- and
hospital-acquired isolates from both sterile and non-sterile sites.
Academic networks tended to focus AMR surveillance around a spe-
cific clinical question, e.g. one project of the Asian Network for
Surveillance of Resistant Pathogens (ANSORP) evaluated susceptibility
of ESBL-producing isolates collected in the region to different antimi-
crobials (Tables 1 and 2). Other academic networks such as the
WorldWide Antimalarial Resistance Network (WWARN) part of the
newly established Infectious Diseases Data Observatory (IDDO) and
International Epidemiologic Databases to Evaluate AIDS (IeDEA)
have led analyses of individual patient data collected by other
research groups.
The approaches taken for drug resistance surveillance by the
major global programmes (TB, malaria, HIV, bacteria, influenza)
are summarized in Table 3. As shown, the TB, malaria and HIV net-
works take an active approach to AMR surveillance in LMICs while
the antibacterial and influenza networks rely on case-based sur-
veillance from sentinel sites.
Networks for AMR surveillance in animals
There is one supranational European network for surveillance of
food- and waterborne diseases and zoonoses that collects data on
antimicrobial susceptibility in humans, animals and food. Larger
networks that monitor foodborne infections [WHO Global
Foodborne Infections network (GFN) and PulseNet International],
including animal and environmental isolates, do not report AMR
data although GFN does support an external quality assurance
(EQA) programme for participating laboratories, which includes
antimicrobial susceptibility testing (AST). No other supranational
networks for AMR surveillance in animals were identified.
Quality management
The networks had different approaches to quality management
(Table 4). The pharma-led networks typically did not involve LMIC
laboratories in EQA programmes but sent all isolates to a central
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laboratory for confirmatory testing. The global surveillance pro-
grammes for AMR in TB, HIV, influenza and gonorrhoea all had profi-
ciency testing programmes delivered via supranational networks of
reference laboratories. Among the networks for AMR surveillance in
bacteria, the Latin-American network, Red Latinoamericana de
Vigilancia de la Resistencia a los Antimicrobianos (ReLAVRA) has
been running an EQA scheme (LA-EQAS) since 2000 and provides
proficiency testing services at no cost to participating laboratories.
The Central Asian and Eastern European Surveillance of
Antimicrobial Resistance (CAESAR), the non-EU European network,
has used the UK National External Quality Assessment Service (UK-
NEQAS) for EQA. WHO-sponsored EQA efforts for AST included the
discontinued WHO EQAS AST (1998–2001)5 and the WHO-AFRO/
NICD-SA EQAP for countries within the WHO-AFRO region.6 Currently
GLASS recommends national reference laboratories take responsibil-
ity for quality management.
Impacts and challenges of the networks
Impacts and challenges of the networks were not recorded consis-
tently. The main themes are summarized in Table 5 with exam-
ples. The biggest challenges faced by the global networks have
been achieving high coverage across LMICs and complying with
the recommended frequency of reporting. The Global Project on
Anti-Tuberculosis Drug Resistance Surveillance has collected resist-
ance data from 155/194 member states since its inception in
1994. For 72 countries without routine drug susceptibility testing of
cases these data come from surveys, which are ideally performed
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Figure 1. Sunburst chart of network types.
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Table 1. AMR surveillance networks for bacteria and fungi in LMICs (arranged in alphabetical order)
Name (acronym), coordinating institution
(if different)
Pathogen category,
network type,
funding type
No. of LMICs/
no. of
countries Years active Description
1 The Alexander Project, GlaxoSmithKline bacteria 4/32 1992–2002 longitudinal multicentre surveillance of
antimicrobial susceptibility of com-
munity-acquired respiratory
pathogens
pharma/CRO
corporate
2 Asian Network for Surveillance of Resistant
Pathogens (ANSORP), Sungkyunkwan
University, Korea
bacteria 8/14 1996–
ongoing
academic regional network with varied
research portfolio; funding sought for
individual projects
academic
corporate, public,
trust or foundation
3 Antimicrobial Resistance Epidemiological
Survey on Cystitis (ARESC), European
Society for Infection in Urology
bacteria 1/10 2003–06 survey of women symptomatic of uri-
nary tract infection (predominantly in
Europe)
academic
corporate
4 Antibiotic Resistance in the Mediterranean
Region (ARMed), Infection Control Unit,
Mater Dei Hospital, Msida, Malta
bacteria 7/9 2003–07 multicentre hospital-based study of
AMR, antibiotic use and infection con-
trol practices
WHO/governmental
public
5 ARTEMIS Global Antifungal Surveillance
Programme (ARTEMIS)
fungi 9/34 1997–2005 longitudinal multicentre surveillance of
Candida spp. and non-candidal yeastspharma/CRO
corporate
6 Assessing Worldwide Antimicrobial
Resistance and Evaluation Programme
(AWARE), International Health
Management Associates, Inc. (IHMA)
bacteria 3/7 2012–
ongoing
ceftaroline surveillance programme
pharma/CRO
corporate
7 Bacterial Infections and Antibiotic-Resistant
Diseases Among Young Children in Low-
Income Countries (BIRDY), Institut
Pasteur International Network
bacteria 3/3 2012–
ongoing
multinational, longitudinal cohort study
of community-acquired and nosoco-
mial infections and drug resistance in
children
academic
corporate, public,
trust or foundation
8 Central Asian and Eastern European
Surveillance of Antimicrobial Resistance
(CAESAR)
bacteria 17/20 2013–
ongoing
European AMR surveillance network for
non-EU countriesWHO/governmental
public
9 Caribbean Public Health Agency (CARPHA) bacteria 10/25 2013–
ongoing
AMR surveillance is one of the agency’s
core activitiesWHO/governmental
trust or foundation
10 Community-Acquired Respiratory Tract
Infection Pathogen Surveillance
(CARTIPS)
bacteria 2/4 2009–10 Asian multicentre AMR surveillance of
community-acquired respiratory
pathogens
pharma/CRO
corporate
11 Centre for Disease Dynamics, Economics
and Policy (CDDEP)/ResistanceMap
bacteria NS 1999–
ongoing
ResistanceMap uses interactive maps
and charts to visualize AMR (and anti-
microbial use) data
academic
trust or foundation,
public
12 Community-Based Surveillance of
Antimicrobial Use and Resistance in
Resource-Constrained Settings, WHO
bacteria 2/2 2002–05 pilot AMR and AMU surveillance projects
at five sites in India and South Africaacademic
public
13 Comparative Activity of Carbapenem
Testing (COMPACT and COMPACT II),
Janssen Asia-Pacific
bacteria 3/5 2008–10 assessment of carbapenem susceptibil-
ity of Gram-negative bacteria isolated
from hospitalized patients in the Asia-
Pacific region
pharma/CRO
corporate
14 International Daptomycin Surveillance
Programmes, JMI Laboratories
bacteria 12/33 2011–
ongoing
assessment of daptomycin susceptibility
of various Gram-positive clinical
isolates
pharma/CRO
corporate
15 Diseases of the Most Impoverished Typhoid
Study Group and Multicentre Shigellosis
Surveillance Study (DOMI), International
Vaccine Institute, Republic of Korea
bacteria 5/5 2001–04 population-based surveillance studies in
Asia with antimicrobial susceptibility
of isolates from confirmed cases
academic
trust or foundation
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Table 1. Continued
Name (acronym), coordinating institution
(if different)
Pathogen category,
network type,
funding type
No. of LMICs/
no. of
countries Years active Description
16 European Antimicrobial Resistance
Surveillance Network (EARS-Net), ECDC
bacteria 2/29 1999–
ongoing
European AMR surveillance network for
EU countriesWHO/governmental
public
17 Enter-Net International Surveillance
Network, Health Protection Agency, UK
bacteria 1/28 1993–2007 European foodborne infection/AMR sur-
veillance network; transferred to
ECDC (FWD-Net)
WHO/governmental
public
18 Food- and Waterborne Diseases and
Zoonoses Network (FWD-Net), ECDC
bacteria 2/29 2007-
ongoing
European surveillance network for food-
and waterborne diseases (includes
AMR), for EU countries
WHO/governmental
public
19 Gonococcal Antimicrobial Surveillance
Programme (GASP), WHO
bacteria 32/70 1992–
ongoing
global network for sentinel surveillance
of AMR (especially cephalosporins) in
N. gonorrhoeae
WHO/governmental
public
20 Global Point Prevalence Survey of
Antimicrobial Consumption and
Resistance (Global-PPS), University of
Antwerp
bacteria 24/63 2015–
ongoing
multicentre point prevalence survey of
antimicrobial prescribing and resist-
ance in hospitalized patients
academic
corporate
21 International Network For Optimal
Resistance Monitoring (INFORM), IHMA
bacteria NS 2012–14 Asia-Pacific, Latin America, Middle East,
Africa, Europepharma/CRO
corporate
22 International Nosocomial Infection Control
Consortium (INICC)
bacteria 32/43 2002–
ongoing
main focus is on the reduction of health-
care-associated infections; collects
associated AMR data
academic
trust or foundation
23 International Network for the Study and
Prevention of Emerging Antimicrobial
Resistance (INSPEAR), US CDC
bacteria 9/30 1998–2010 AMR early warning system with profi-
ciency testing for laboratories and
expedited reporting of drug-resistant
infections
academic
public
24 In Vitro Activity of Oral Antimicrobial Agents
Against Pathogens Associated With
Community-Acquired Upper Respiratory
Tract and Urinary Tract Infections: A Five
Country Surveillance Study, IHMA
bacteria 2/5 2012–13 global surveillance of susceptibility of
community-acquired respiratory and
urinary tract pathogens
pharma/CRO
corporate
25 Multiyear, Multinational Survey of the
Incidence and Global Distribution of MBL-
Producing Enterobacteriaceae and
Pseudomonas aeruginosa, IHMA
bacteria 12/31 2012–14 global hospital-based surveillance of
MBL-producing Gram-negative
bacteria
pharma/CRO
corporate
26 Minocycline activity tested against
Acinetobacter baumannii complex,
Stenotrophomonas maltophilia and
Burkholderia cepacia species complex iso-
lates from a global surveillance pro-
gramme (2013), JMI Laboratories
bacteria NS/46 2013 AMR surveillance in Gram-negative
organisms focused on assessment of
minocycline activity
pharma/CRO
corporate
27 Meropenem Yearly Susceptibility Test
Information Collection (MYSTIC),
AstraZeneca
bacteria 8/21 1997–2008 assessment of meropenem susceptibil-
ity of various clinical isolates from
patients with serious infections.
pharma/CRO
corporate
28 Network for Surveillance of Pneumococcal
Disease in the East Africa Region
(netSPEAR)
bacteria 4/4 2003–07 East African network that strengthened
routine surveillance of Streptococcus
pneumoniae and Haemophilus
influenzae infections in children (labo-
ratory and data-management train-
ing, improved communication)
academic
trust or foundation
Continued
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Table 1. Continued
Name (acronym), coordinating institution
(if different)
Pathogen category,
network type,
funding type
No. of LMICs/
no. of
countries Years active Description
29 NosoMed Pilot Survey in the Eastern
Mediterranean Area, Universite´ Claude
Bernard Lyon I
bacteria 2/3 2003–04 multicentre surveillance of drug-resist-
ant nosocomial bacterial isolatesacademic
public
30 Programme to Assess Ceftolozane/
Tazobactam Susceptibility (PACTS), Cubist
Pharmaceuticals
bacteria 2/16 2012–
ongoing
ceftolozane/tazobactam susceptibility
surveillance programme focused on
nosocomial infections
pharma/CRO
corporate
31 Pan-European Antimicrobial Resistance
Using Local Surveillance (PEARLS), Wyeth
Pharmaceuticals
bacteria 4/17 2001–02 AMR surveillance of nosocomial isolates
of Enterococcus faecium, Enterobacter
cloacae, Enterobacter aerogenes,
E. coli, Klebsiella pneumoniae,
S. aureus
pharma/CRO
corporate
32 Prospective Resistant Organism Tracking
and Epidemiology for the Ketolide
Telithromycin (PROTEKT), Sanofi-Aventis
bacteria 10/36 1999–2004 international AMR surveillance of com-
munity-acquired respiratory tract
pathogens
pharma/CRO
corporate
33 Red Latinoamericana de Vigilancia de la
Resistencia a los Antimicrobianos
(ReLAVRA), PAHO
bacteria 15/19 1996–
ongoing
Latin-American AMR surveillance net-
work with a proficiency testing
programme
WHO/governmental
public
34 South Asian Pneumococcal Alliance
(SAPNA), GAVI Alliance
bacteria 3/3 2004–09 AMR surveillance of infections caused by
S. pneumoniae, H. influenzae and
N. meningitidis in South Asian children
academic
public, corporate
35 Study on Antimicrobial Resistance in
Staphylococcus aureus (SARISA), LEO
Pharma (Copenhagen)
bacteria 2/18 1996–
ongoing
multicentre survey of AMR in S. aureus
pharma/CRO
corporate
36 SENTRY Antimicrobial Surveillance
Programme, JMI laboratories
bacteria, fungi 8/40 1997–
ongoing
monitors antimicrobial susceptibility in a
wide variety of community-acquired
and nosocomial pathogens
pharma/CRO
corporate
37 Sistema de Redes de Vigilancia de los
Agentes Responsables de Neumonias y
Meningitis Bacterianas (SIREVA and
SIREVA II), PAHO
bacteria 15/19 1993–
ongoing
Latin-American regional network for
surveillance of respiratory and menin-
gitis pathogens
WHO/governmental
public
38 Study for Monitoring Antimicrobial
Resistance Trends (SMART), Merck & Co.
Inc.
bacteria 23/53 2002–11 AMR surveillance of Gram-negative clini-
cal isolates from intra-abdominal
infections and urinary tract infections
pharma/CRO
corporate
39 Survey of Antibiotic Resistance (SOAR),
GlaxoSmithKline
bacteria 34/48 2002–
ongoing
a series of studies of antimicrobial sus-
ceptibility of pathogens causing com-
munity-acquired respiratory infection
pharma/CRO
corporate
40 International Solithromycin Surveillance
Programmes, JMI Laboratories, USA
bacteria 5/27 2011–
ongoing
AMR surveillance in Gram-positive
organisms focused on assessment of
solithromycin activity
pharma/CRO
corporate
41 TARGETed Surveillance Study, GR Micro Ltd,
UK
bacteria 2/7 2003–07 AMR surveillance of community-
acquired respiratory tract pathogens
with a focus on fluoroquinolone
activity
pharma/CRO
corporate
42 Tigecycline Evaluation and Surveillance Trial
(TEST), IHMA
bacteria 25/65 2004–
ongoing
global, hospital-based AMR surveillance
of a wide range of clinical isolates
with a focus on tigecycline
susceptibility
pharma/CRO
corporate
43 Typhoid Fever Surveillance in Africa
Programme (TSAP), International Vaccine
Institute, Korea
bacteria 10/10 2009–
ongoing
multinational, population surveillance
study of typhoid incidence in Africa
(included AST of invasive isolates)
academic
trust or foundation
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every 5 years. The biggest gaps in surveillance in the most recent
report were over West and central Africa. At an individual level it
was estimated that 33% of new TB cases and 60% of cases treated
previously underwent rifampicin susceptibility testing in 2016.7
Only one-third of 106 malaria endemic countries were in compli-
ance with the recommended targets for antimalarial drug efficacy
surveillance (monitoring at three-yearly intervals) when last
reported, although the Global Malaria Programme has recently
updated its web site with aggregate data from more
studies.8,9 The Gonococcal Antimicrobial Surveillance Programme
(GASP) has had no regional focal point in Africa since 2012. The
WHO 2014 Global Report on Surveillance obtained data on antimi-
crobial susceptibility in N. gonorrhoeae from only 42/194 (22%)
member states and noted that coverage was poorest from pre-
sumed high-burden countries. WHO GISRS reported resistance to
the neuraminidase inhibitors of influenza viruses in 2016. Out of
13 312 viruses collected by National Influenza Centres between
May 2014 and May 2015, 94% were from three WHO regions:
Western Pacific, the Americas and Europe, with only 3% from
Africa and 2% from Southeast Asia.10 WHO is in the process of
developing a new Global Action Plan for HIV drug resistance. In
July 2016 it was reported that 59/144 LMICs had monitored for the
emergence of HIV drug resistance using the recommended early
warning indicator system, which looks at antiretroviral treatment
coverage, retention in care, treatment interruption and viral load
suppression.11 A meta-analysis in 2012 reported HIV-1 drug resist-
ance surveillance data from 42 LMICs between 2001 and 2011,
and 8 countries performed surveys for pre-treatment HIV DR
between 2014 and May 2016.12,13
In a detailed account of the experience of setting up the
Network for Surveillance of Pneumococcal Disease in the East
Africa Region (netSPEAR), an East African network funded by the
GAVI Alliance, in which routine surveillance for pneumococcal dis-
ease in public hospitals was strengthened, key challenges noted
were difficulty in engaging the government of one of the partici-
pating countries in the network, poor performance of some sites
despite training and problems with attracting funding.14 The
importance of national and institutional ownership of surveillance
activity and of framing it as part of routine activity rather than
extra work was stressed. The benefits of collaboration between
policymakers, academics and service providers were highlighted, a
sentiment echoed by the experience of the malaria regional net-
works, which re-energized surveillance and also played a role in
advocacy for policy change, acting as a bridge between research
groups and national control programmes.4 Individual patient data
meta-analyses coordinated by WWARN have led to policy recom-
mendations to change antimalarial drug dosing. Another impact
of the academic malaria drug efficacy surveillance networks has
been the establishment of successful North–South scientific part-
nerships. There are a few examples where the scientific leadership
now comes from the South, e.g. Plasmodium Diversity Network
Africa, a molecular surveillance network.15
Surveillance networks have a positive impact by connecting lab-
oratories in different countries. The Antibiotic Resistance in the
Mediterranean Region (ARMed) network, which ran between 2003
and 2007, reported improvement in participating laboratories’
capacity to perform bacterial identification and AST, as a result of
the EQA programme attached to the network.16 The HIV, myco-
bacteria, influenza and gonorrhoea reference laboratory networks
have been created thanks to global surveillance programmes.
Discussion
Defining the global burden of AMR and monitoring the impact of
interventions to counter it requires reliable surveillance data.
LMICs shoulder the bulk of the global burden of infectious diseases
and drug resistance but their surveillance systems tend to be
weaker than those in high-income countries (HICs), because pas-
sive surveillance cannot be integrated with routine case-
management of patients easily in many areas. This problem has
been circumvented to an extent in TB, malaria and HIV AMR sur-
veillance by using active approaches to surveillance in LMICs and
gathering data intermittently to provide a snapshot of the situa-
tion. However, achieving high coverage of all LMICs and complying
with the recommended frequency of surveillance has been diffi-
cult. A review of the HIV, TB and malaria surveillance systems in
2011 suggested that one risk of integrating surveillance into rou-
tine activities was that high-quality implementation was less
likely.17 By contrast, GLASS is based on building up or strengthening
traditional models of passive case-based surveillance to generate
data, as in HICs. Priority pathogens, drugs and specimens for sur-
veillance are named but, unlike the other networks, GLASS does
not specify minimum sample sizes or detailed selection criteria for
target populations. Responsibility for quality management is
devolved to national reference centres rather than a supranational
body. Member states are requested to submit their AMR data to
Table 1. Continued
Name (acronym), coordinating institution
(if different)
Pathogen category,
network type,
funding type
No. of LMICs/
no. of
countries Years active Description
44 WHO Western Pacific Regional Programme
for Surveillance of Antimicrobial
Resistance
bacteria 6/13 1991–98 regional network for antimalarial thera-
peutic efficacy monitoringWHO/governmental,
academic
public
45 ZyvoxV
R
Annual Appraisal of Potency and
Spectrum (ZAAPS), JMI Laboratories, USA
and Pfizer
bacteria 12/42 2004–
ongoing
global monitoring of linezolid activity
against Gram-positive bacteriapharma/CRO
corporate
PAHO, Pan American Health Organization; CRO, contract research organization; NS, not specified.
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Table 2. AMR surveillance networks for malaria, HIV, TB and influenza in LMICs (arranged by pathogen and in alphabetical order)
Name (acronym), coordinating insti-
tution if different
Pathogen category, net-
work type, funding type
No. of LMICs/
no. of
countries Years active Description
Malaria
1 Amazon Malaria Initiative (AMI),
PAHO
malaria 11/12 2001–ongoing Latin-American regional antimalarial
resistance surveillance network;
some overlap with RAVREDA
WHO/governmental
public
2 Artemisinin Resistance Confirmation,
Characterization and Containment
Collaboration (ARC3), WHO
malaria 3/3 2009–10 multicentre study of artemisinin
resistance in Southeast Asiaacademic
trust or foundation, public
3 Artemisinin Resistance Containment
and Elimination Collaboration
(ARCE), WHO
malaria 3/3 2010–11 multicentre artemisinin-resistant
malaria containment and elimina-
tion project
academic
trust or foundation, public
4 Bangladesh, Bhutan, India, Nepal, Sri
Lanka Malaria Drug Resistance
Network (BBINS)
malaria 5/5 2011–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
5 East African Network for Monitoring
Antimalarial Treatment (EANMAT)
malaria 5/5 1997–2006 regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental,
academic
public
6 Greater Mekong Sub-region
Therapeutic Efficacy Studies (TES)
Network
malaria 8/8 2007–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
7 Horn of Africa Network for Monitoring
Antimalarial Treatment (HANMAT)
malaria 5/6 2004–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
8 K13 Artemisinin Resistance
Multicentre Assessment
Consortium (KARMA), Institut
Pasteur
malaria 56/59 2014–ongoing multinational molecular genotyping
trials to map the kelch 13
mutation
academic
public
9 MalariaGEN Genomic Epidemiology
Network, MalariaGEN Resource
Centre
malaria
academic
trust or foundation
36/36 2005–ongoing Global network focusing on analysis
of genetic/genomic data
10 Plasmodium Diversity Network Africa
(PDNA), University of Science,
Techniques and Technologies,
Bamako, Mali
malaria 15/15 2012–ongoing African network mapping malaria
parasite genetic diversity and
molecular markers of drug
resistance
academic
public, trust or foundation
11 Pacific Malaria Drug Resistance
Monitoring Network
malaria 7/8 2011–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
12 Pakistan-Iran-Afghanistan Malaria
Network
malaria 3/3 2008–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
13 Reseau d’Afrique Centrale pour
Traitement Anti-Paludisme
(RACTAP)
malaria 8/8 2003–09 regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
14 Amazon Network for the Surveillance
of Antimalarial Drug Resistance
(RAVREDA)
malaria 12/13 2001–ongoing regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
public
15 South African Network for the
Monitoring of Antimalarial Drug
Resistance (SANMAT)
malaria 7/7 2002–14 regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental
academic
public
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the WHO global antimicrobial susceptibility database (WHONET).
The experiences of ReLAVRA, the Latin-American network, and, to
an extent, CAESAR, the newer European network, have shown that
case-based surveillance can be implemented in middle-income
countries but obtaining representative data may take time. It is
likely that it will be many more years before most low-income
Table 2. Continued
Name (acronym), coordinating insti-
tution if different
Pathogen category, net-
work type, funding type
No. of LMICs/
no. of
countries Years active Description
16 Tracking Resistance to Artemisinin
Collaboration (TRAC and TRAC2),
Mahidol Oxford Tropical Medicine
Research Unit
malaria 10/10 2011–ongoing multinational clinical trials to map
artemisinin resistanceacademic
public
17 West African Network for Monitoring
Antimalarial Treatment
(WANMAT)
malaria 15/15 2003–09 regional network for antimalarial
therapeutic efficacy monitoringWHO/governmental,
academic
public
18 WorldWide Antimalarial Resistance
Network (WWARN)
malaria 37/70 2009–ongoing collates antimalarial resistance data
from other groups and performs
individual patient data meta-
analyses
academic
corporate, trust or
foundation
HIV
1 Europe Africa Research Network for
Evaluation of Second-Line Therapy
(EARNEST)
HIV 4/4 2010–11 academic network focused on HIV
resistance to second-line thera-
pies in Africa
academic
public
2 Global HIV Drug Resistance Network
(HIVResNet), WHO
HIV 15/23 2007–ongoing global network of experts from aca-
demic institutions, laboratories
and international and non-profit
organizations
WHO/governmental
public
3 International Epidemiologic
Databases to Evaluate AIDS
(IeDEA), NIAID
HIV 36/47 2005–ongoing platform for data sharing from differ-
ent sites, used to address research
questions
academic
public
4 PharmAccess African Studies to
Evaluate Resistance (PASER),
PharmAccess Foundation, AIGHD
and Virology Department at the
University Medical Centre, Utrecht,
The Netherlands
HIV 6/6 2006–15 multinational HIV DR surveillance in
Africaacademic
public
5 TREAT Asia Studies to Evaluate
Resistance (TASER)
HIV 5/6 2007–11 HIV DR surveillance programme
linked to TREAT Asia studiesacademic
public, trust or foundation
6 Tenofovir Resistance Study Group
(TenoRES)
HIV 10/23 2015–16 pooled-data analysis of tenofovir
and other antiretroviral resistance
in HIV
academic
trust or foundation
TB
1 Comprehensive Resistance Prediction
for Tuberculosis International
Consortium (CRyPTIC), University
of Oxford
TB 5/10 2015–ongoing WGS of isolates from multiple loca-
tions to investigate genomic varia-
tion associated with drug
resistance
academic
trust or foundation
2 WHO/IUATLD Global Project on Anti-
Tuberculosis Drug Resistance
Surveillance (WHO/IUATLD)
TB 39/89 1994–ongoing global surveillance programme with
associated supranational refer-
ence laboratory network
WHO/governmental
public
Influenza
1 WHO Global Influenza Surveillance
and Response System (WHO
GISRS)
influenza 67/113 1947–ongoing global surveillance for susceptibility
of influenza viruses to neuramini-
dase inhibitors
WHO/governmental
public
AIGHD, Amsterdam Institute for Global Health and Development; PAHO, Pan American Health Organization; DR, drug resistance.
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Table 3. Approaches to AMR surveillance taken by global WHO programmes in LMICs
TB Malaria HIV
Bacteria
(GLASS!GASP) Influenza (GISRS)
Type(s) of
surveillance
epidemiological sur-
veys or case
notification
therapeutic efficacy
studies at sentinel
sites and molecular
marker surveys
EWIa; two types of
molecular marker
surveys (PDR and
ADR)b
routine surveillance
of clinical isolates
at sentinel sites
case-based surveil-
lance from sentinel
sites
Technology/labora-
tory methods
culture and sus-
ceptibility testing;
GeneXpertV
R
;
other molecular
methods
microscopy and PCR-
based technologies
PCR based culture and suscepti-
bility testing
RT-PCR based; HAI test;
virus isolation in cell
culture and suscepti-
bility testing at refer-
ence laboratories
Defined selection
criteria for popu-
lation of interest
yes yes yes no yes – clinical case
definition
Recommended
sample size
yes yes yes no no
Recommended fre-
quency of
surveillance
every 5 years (sur-
vey-based meth-
odology); contin-
uous (if case-
based
surveillance)
every 3 years every 3 years annual continuous
Data sharing
mechanism
WHO Global TB
Database
WHO Global Malaria
Programme
Database
no WHONET FluNet
Regional surveil-
lance networks
no yes no yes no
surveillance data
consolidated in
WHO regional
offices
BBINS, MBDS network,
HANMAT, RAVREDA,
PDRMN (other
regional networks
have collapsed due
to lack of funding)
HIVResNet is a global
network of experts
from academic insti-
tutions, laboratories
and non-profit
organizations cre-
ated in 2007 to
develop strategies to
monitor HIV DR
GLASS: Europe (EARS-
Net; CAESAR) and
Latin America
(ReLAVRA); GASP
data collated via
WHO Regional
Office/Reference
Centres (except
Africa)
GISRS is a network of
National Influenza
Centres (NICs) and
WHO Collaborating
Centres (WHOCCs)
Reference labora-
tory network(s)
yes no yes – yes
WHO TB suprana-
tional reference
laboratory
network
global HIV drug resist-
ance laboratory
network
GLASS—no; GASP—
yes
NICs; WHOCCs; WHO
H5 Reference
Laboratories
Global proficiency
testing scheme
yes no no no yes
participation in an EQA
scheme is a prereq-
uisite to becoming a
WHO-designated
genotyping
laboratory
no global scheme
proposed in GLASS;
ReLAVRA—LA-
EQAS; CAESAR—
UK-NEQAS; GASP -
EQAS
WHO-EQAP
Guidance on use of
AMR surveillance
data
individual case
management
and to guide
design of new
second-line
treatment
regimens
defined cut-offs for
considering national
treatment policy
change
used to support choice
of nationally recom-
mended ART and
prophylaxis
regimens
to inform treatment
guidelines
to improve antiviral use
in treatment and for
pandemic
preparedness
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countries have a well-functioning system for routine bacteriologi-
cal surveillance with high coverage. As a result, this approach risks
generating non-representative data in the short- to medium-
term, as has happened so far, and making inter-country compari-
sons will be difficult. The long-established WHO/International
Union Against Tuberculosis and Lung Disease (WHO/IUATLD) sur-
veillance programme had been described as the ‘pathfinder’ for
GLASS but is at a considerable advantage with the development of
robust molecular detection methods, notably the roll-out of
GeneXpertV
R
, a PCR-based technology that can be performed
Table 3. Continued
TB Malaria HIV
Bacteria
(GLASS!GASP) Influenza (GISRS)
Frequency of
reporting
annual every 5 years20 ad hoc; HIV DR global
action plan under
development
GLASS—first report
January 2018;
GASP—ad hoc
(every 3 years
approx.)
biennial (influenza virus
surveillance report-
ing is available in
real time)
MBDS, Mekong Basin Disease Surveillance; PDRMN, Pacific Malaria Drug Resistance Monitoring Network; DR, drug resistance.
aEWI" early warning indicator, e.g. antiretroviral coverage, retention in care, treatment interruption and viral load suppression.
bADR"acquired HIV drug resistance and PDR"pretreatment HIV drug resistance.
Table 4. AMR-related proficiency testing and quality management in the networks
Name (acronym) of programme/country location
of head office Years active Description
1 Global Laboratory Initiative (GLI), for the Global TB
Programme/Switzerland
2008–ongoing standards and/or policy setting, proficiency testing, training
2 WHO HIVResNet Laboratory Accreditation Scheme/
Switzerland
2007–ongoing accreditation body; national HIV drug resistance working
groups coordinating WHO-recommended surveys must
use a WHO-designated genotyping laboratory
3 ReLAVRA Latin America External Quality Assessment (LA-
EQAS)/Argentina
2000–ongoing proficiency testing for the ReLAVRA network
4 TREAT Asia Quality Assessment Scheme(TAQAS)/
Australia
2006–ongoing TREAT Asia (an amfAR programme) aims to standardize HIV-
1 genotypic resistance testing among laboratories to per-
mit comparison of results from different centres
5 UK External Quality Assurance Scheme (UK NEQAS)/UK 1969–ongoing offers proficiency testing in bacteriology and other laboratory
disciplines; .8000 labs from over 140 countries
participate
6 World Health Organization (WHO)/Switzerland 2003–ongoing issues guidelines and sets policy
7 WHO African Region External Quality Assurance
Programme (WHO AFRO EQAP)/South Africa
2002–ongoing proficiency testing; 81 laboratories from 45 countries in the
WHO African Region participate in the programme; in
2012 it was reported that 20% of labs did not respond to
the surveys
8 WHO External Quality Assessment Project for the
Detection of Subtype Influenza A Viruses by PCR/
Switzerland
2007–ongoing the EQA Project is conducted jointly by WHO Headquarters,
WHO H5 Reference Laboratory and National Influenza
Centre, China Hong Kong SAR, with support from the WHO
Collaborating Centres on influenza and other WHO H5
Reference Laboratories
9 WHO Global Foodborne infections Network (WHO GFN)
EQAS/Denmark
2000–ongoing proficiency testing (pathogen identification, serotyping and
AST) organized by the National Food Institute, Denmark
10 WHO Gonococcal Surveillance Programme EQAS 1992–ongoing WHO Collaborating Centre in Sydney manages SE Asia/Asia-
Pacific programmes
11 WHO Mycobacterial Supranational Reference Laboratory
(SRL) Network/Switzerland
1991–ongoing network of 33 laboratories providing reference laboratory
services and proficiency testing
12 WHO External Quality Assurance System for
Antimicrobial Susceptibility Testing (EQAS-AST)/
Switzerland
1998–2006 proficiency testing programme in bacterial isolates (identifi-
cation and AST)
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directly on primary TB specimens without an intermediate culture
step.18 Molecular surveillance for drug resistance in other bacteria
remains some way off but should be made a high priority in order
to simplify surveillance in LMICs.
Assessing the representativeness of AMR surveillance data
presents a particular challenge. This will be affected by the geo-
graphical location and number of sentinel sites, the number and
characteristics of individuals sampled, prior treatment history, the
incidence of the target pathogen and the methods of detection.
WHO/IUATLD has developed its surveillance methodology to the
point where it uses survey data to estimate MDR-TB incidence
worldwide but this is exceptional for the global programmes. The
global report on early warning indicators of HIV drug resistance
states that data from most countries cannot be considered as rep-
resentative due to the way in which the clinics sampled were
selected.11 In malaria therapeutic efficacy studies in high-
transmission settings, children less than five years of age are
studied since they have the lowest levels of acquired immunity to
malaria to give a ‘worst-case scenario’ depiction of drug efficacy.
AMR surveillance for the most commonly encountered bacteria, as
it has been practised to date, presents more problems than for
other pathogens because of the lack of agreed case definitions and
standardized sampling methods. An analysis comparing trends
in Escherichia coli resistance from 1997 to 2001 reported by the
global Meropenem Yearly Susceptible Test Information Collection
(MYSTIC) and SENTRY pharma networks showed that, despite col-
lecting isolates from similar geographical areas, estimates of non-
susceptibility from MYSTIC were consistently higher than those
from SENTRY. However, further analysis revealed this was due to a
higher proportion of isolates from patients in ICUs in MYSTIC.19
AMR surveillance in animals is still in its infancy, with the excep-
tion of foodborne infections, but some strategies have been piloted
in LMICs under the guidance of the WHO Advisory Group on
Integrated Surveillance of Antimicrobial Resistance (AGISAR). The
challenges are great, e.g. progress towards standardizing AST
breakpoints in veterinary microbiology is far behind that made in
humans.
Other networks deserving of a mention that were not included
in this analysis are two Digital Disease Detection networks, ProMed
and HealthMap, which publish sporadic AMR reports and have an
advantage over other networks for the rapidity with which they
disseminate information. There is potential for overlap between
the activities of networks for AMR detection, foodborne infections
and emerging disease detection.
The main limitation of our approach is that the heterogeneity of
the data meant meta-analysis was not possible. There are no rec-
ognized standards for the composition and activities of AMR sur-
veillance networks. Impacts and challenges of the networks were
reported infrequently and our assessment is reliant on published
information, which may be more likely to report challenges. In
addition, our search was only performed in English with a supple-
mentary search in Spanish to obtain more information about the
Latin-American networks.
A successful AMR surveillance network should generate up-to-
date comparable, representative, high-quality data on pathogens
of concern from the target population(s). It should be able to detect
and track unexpected events including outbreaks in real time, have
rapid, effective mechanisms for communication and reporting, and
have a responsible data-sharing policy. A network needs strong
leadership and coordination, and it should influence guidelines and
policy and ultimately impact on human and animal health. Very
few networks were instigated to specifically monitor intervention
programmes, e.g. the International Nosocomial Infection Control
Consortium. Linking surveillance activity to interventions to combat
drug resistance has the potential to increase their impact.
Pharma networks produce high-quality data, but they may not
be representative and these networks do not usually support labo-
ratory capacity building in LMICs or influence policy and guidelines.
Purely academic networks also produce high-quality data; they
often target a clinical or policy question, but they too have limited
influence on policy and their sustainability is reliant on external
funding. Most of the networks are slow to report their findings and
do not give unrestricted access to their data. The experience of the
larger global programmes for AMR surveillance in TB, malaria and
Table 5. Impacts and challenges of the AMR surveillance networks in LMICs with examples
Impacts Challenges
• Led to changes in treatment policy (malaria networks)
• Improved laboratory capacity by establishing networks of reference lab-
oratories and quality management systems (ARMed, WHO/IUATLD,
GASP, ReLAVRA, CAESAR)
• Standardization of surveillance methodologies and data analysis (WHO
Global Malaria Programme, ReLAVRA, WHO/IUATLD, HIVResNet,
WHONET, WWARN)
• Reduction in healthcare-associated infections in countries (INICC)21,22
• Exchange of information, training and knowledge between countries
(WHO, ReLAVRA, WWARN, netSPEAR)
• Data sharing with secondary benefits to inform treatment guidelines
(WWARN, IeDEA)
• Created global repositories of bacterial isolates; these can be used to
screen new drugs (SENTRY, ANSORP)
• Discovery of new resistance mechanisms (The Alexander Project)
• Low coverage, particularly in sub-Saharan Africa and India (GASP,
GISRS)
• Lack of representativeness of data, e.g. due to selective sampling
(HIV, GASP, some CAESAR sites)
• Difficulties of implementing routine blood culture/diagnostic
microbiology in clinical practice (CAESAR)
• Difficulties in implementing complex surveillance methodologies,
e.g. optimal in vivo methods for surveillance for artemisinin resist-
ance in malaria, second-line drug susceptibility testing for TB
• Lack of engagement by some partners (netSPEAR)
• Reporting delays
• Sustainability due to underfunding with consequent understaff-
ing; surveillance has generally not been given high priority by
external donors (EANMAT, netSPEAR)
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HIV suggests that options for more active surveillance may need
to be considered in order to gather comparable useful data from
low-income countries before reliable case-based surveillance can
be established.
Maintaining an up-to-date registry of networks would
promote a more coordinated approach to surveillance, reduce
duplication of efforts, optimize funding investment and improve
sustainability.
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